InflaRx (IFRX) Total Current Liabilities (2016 - 2026)
InflaRx (IFRX) posted Total Current Liabilities of $13.3 million for Q1 2026, down 11.75% sequentially from $15.1 million in Q4 2025, and down 21.75% YoY from $17.0 million in Q1 2025.
InflaRx (IFRX) Total Current Liabilities (2016 - 2026) Analysis & Trends
InflaRx has reported Total Current Liabilities for 11 years, with the latest figure at $13.3 million in Q1 2026.
- Quarterly Total Current Liabilities fell 21.75% year-over-year to $13.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.3 million (down 21.75% YoY) and the FY2025 annual result came in at $14.7 million, down 4.34% from the prior year.
- Total Current Liabilities retreated to $13.3 million in Q1 2026 per IFRX's latest filing, from $15.1 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $22.3 million in Q3 2025 and troughed at $7.3 million in Q1 2023.
- A 5-year average of $14.3 million and a median of $13.3 million in 2026 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2022 and 2023: Total Current Liabilities soared 114.31% in 2022, then sank 65.69% in 2023.
- Over 5 years, Total Current Liabilities stood at $13.3 million in 2022, then jumped by 36.37% to $18.1 million in 2023, then decreased by 16.47% to $15.1 million in 2024, then retreated by 0.18% to $15.1 million in 2025, then slipped by 11.75% to $13.3 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $13.3 million, $15.1 million, and $22.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | 23.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.34 Mn |
| Dec 31, 2025 | 15.11 Mn |
| Sep 30, 2025 | 22.27 Mn |
| Jun 30, 2025 | 18.29 Mn |
| Mar 31, 2025 | 17.04 Mn |
| Dec 31, 2024 | 15.14 Mn |
| Sep 30, 2024 | 15.23 Mn |
| Jun 30, 2024 | 11.03 Mn |
| Mar 31, 2024 | 12.57 Mn |
| Dec 31, 2023 | 18.12 Mn |
| Sep 30, 2023 | 11.63 Mn |
| Jun 30, 2023 | 8.13 Mn |
| Mar 31, 2023 | 7.30 Mn |
| Dec 31, 2022 | 13.29 Mn |
| Sep 30, 2022 | 10.65 Mn |
| Jun 30, 2022 | 12.05 Mn |
| Mar 31, 2022 | 21.27 Mn |
| Dec 31, 2021 | 21.46 Mn |
| Sep 30, 2021 | 15.28 Mn |
| Jun 30, 2021 | 12.21 Mn |